Publications
Selected Publications
Egger K*, Jareño Redondo J*, Müller J, Dornbierer J, Smallridge J, Aicher HD, Meling D, Müller P, Kost J, Puchkov M, Äbelö A, Seifritz E, Quednow BB, von Rotz R, Scheidegger M, Dornbierer DA. Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study. Biomed Pharmacother. 2025 Mar;184:117908. https://doi.org/10.1016/j.biopha.2025.117908
Mueller MJ*, Aicher HD*, Dornbierer DA*, Marten L, Suay D, Meling D, Elsner C, Wicki IA, Müller J, Poetzsch SN, Caflisch L, Hempe A, Steinhart CP, Puchkov M, Kost J, Landolt HP, Seifritz E, Quednow BB, Scheidegger M. Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial. Int J Neuropsychopharmacol. 2025 Jan 8:pyaf001. https://doi.org/10.1093/ijnp/pyaf001
Suay D, Aicher HD, Singer B, Mueller MJ, Jelusic A, Calzaferri L, Springfeld P, Dornbierer DA, Scheidegger M. Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation. J Psychopharmacol. 2025 Aug 16:2698811251353256. https://doi.org/10.1177/02698811251353256
Egger K, Meling D, Polat F, Seifritz E, Avram M, Scheidegger M. Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat. Imaging Neurosci (Camb). 2025 Sep 29;3:IMAG.a.907. https://doi.org/10.1162/imag.a.907
Aicher HD*, Wicki IA*, Meling D, Mueller MJ, Dornbierer DA, Scheidegger M. Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects. J Psychopharmacol. 2025 Jun 19:2698811251344689. https://doi.org/10.1177/02698811251344689
Meling D, Egger K, Aicher HD, Jareño Redondo J, Mueller J, Dornbierer J, Temperli E, Vasella EA, Caflisch L, Pfeiffer DJ, Schlomberg JT, Smallridge JW, Dornbierer DA, Scheidegger M. Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. J Psychopharmacol. 2024 Oct;38(10):897-910. https://doi.org/10.1177/02698811241282637
Egger K, Aicher HD, Cumming P, Scheidegger M. Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cell Mol Life Sci. 2024 Sep 10;81(1):395. https://doi.org/10.1007/s00018-024-05353-6
Aicher HD*, Mueller MJ*, Dornbierer DA, Suay D, Elsner C, Wicki I, Meling D, Caflisch L, Hempe A, Steinhart C, Mueller J, Von Rotz R, Kleim B, Scheidegger M. Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. Front Psychiatry. 2024 Jan 8;14:1302559. https://doi.org/10.3389/fpsyt.2023.1302559
Dornbierer DA, Marten L, Mueller J, Aicher HD, Mueller MJ, Boxler M, Kometer M, Kosanic D, von Rotz R, Puchkov M, Kraemer T, Landolt HP, Seifritz E, Scheidegger M. Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. Front Pharmacol. 2023 Nov 27;14:1246892. https://doi.org/10.3389/fphar.2023.1246892
Meling D, Scheidegger M. Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective. Front Psychol. 2023 Apr 3;14:1100058. https://doi.org/10.3389/fpsyg.2023.1100058